This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AYLA Ayala Pharmaceuticals (AYLA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Ayala Pharmaceuticals Stock (NASDAQ:AYLA) 30 days 90 days 365 days Advanced Chart Get Ayala Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.50▼$0.5050-Day Range$0.38▼$0.5852-Week Range$0.36▼$7.31VolumeN/AAverage Volume76,300 shsMarket Capitalization$7.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAyala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.Read More… Receive AYLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AYLA Stock News HeadlinesOS Therapies to acquire listeria programs from Ayala PharmaceuticalsJanuary 30, 2025 | markets.businessinsider.comOS Therapies Expands Pipeline With Ayala Asset Acquisition, Stock UpJanuary 29, 2025 | markets.businessinsider.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. June 6, 2025 | Golden Portfolio (Ad)Ayala group building 2nd cold storage facility in CebuAugust 27, 2024 | msn.comADXS Ayala Pharmaceuticals, Inc.August 24, 2024 | seekingalpha.comAyala Pharmaceuticals (ADXS) Earnings Dates & ReportsFebruary 13, 2024 | investing.comAyala Pharmaceuticals Stock (OTC:ADXS) Dividends: History, Yield and DatesDecember 21, 2023 | benzinga.comAdvaxis, Inc.: Advaxis and Ayala Pharmaceuticals Complete MergerJanuary 19, 2023 | finanznachrichten.deSee More Headlines AYLA Stock Analysis - Frequently Asked Questions How were Ayala Pharmaceuticals' earnings last quarter? Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) released its quarterly earnings results on Monday, November, 15th. The company reported ($0.68) earnings per share for the quarter, topping analysts' consensus estimates of ($0.80) by $0.12. The company earned $0.63 million during the quarter, compared to analysts' expectations of $0.82 million. Ayala Pharmaceuticals had a negative trailing twelve-month return on equity of 182.13% and a negative net margin of 2,341.69%. When did Ayala Pharmaceuticals IPO? Ayala Pharmaceuticals (AYLA) raised $50 million in an initial public offering (IPO) on Friday, May 8th 2020. The company issued 3,300,000 shares at $14.00-$16.50 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Oppenheimer and Raymond James were co-managers. What other stocks do shareholders of Ayala Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ayala Pharmaceuticals investors own include HubSpot (HUBS), Netflix (NFLX), ForgeRock (FORG), Bank of America (BAC), ConocoPhillips (COP) and Diamondback Energy (FANG). Company Calendar Last Earnings11/15/2021Today6/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:AYLA CIK1797336 Webwww.ayalapharma.com Phone857-444-0553FaxN/AEmployees35Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$40.25 million Net Margins-2,341.69% Pretax Margin-2,298.60% Return on Equity-182.13% Return on Assets-139.83% Debt Debt-to-Equity RatioN/A Current Ratio2.28 Quick Ratio2.28 Sales & Book Value Annual Sales$3.51 million Price / Sales2.13 Cash FlowN/A Price / Cash FlowN/A Book Value$2.45 per share Price / Book0.21Miscellaneous Outstanding Shares14,821,000Free Float14,287,000Market Cap$7.46 million OptionableNot Optionable Beta1.98 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:AYLA) was last updated on 6/6/2025 by MarketBeat.com Staff From Our PartnersElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredTrump’s Wealth Reset: Could You Be The First Beneficiary?Trump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major shift is coming this July — and Wall Street isn't waiting around. Thanks to a new rule going into e...American Alternative | SponsoredHow to target 627% gains from Trump’s tweetsPresident Trump is shaking up the market with his tweets and Truth Social posts... But while this chaos has...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.